|Follow up complete
|Study Start Date:
|Study Made Public:
A Phase 1 clinical trial to evaluate the safety and immunogenicity of pDNA vaccines expressing HIV M Group p24Gag conserved elements and/or p55Gag, administered with IL-12 pDNA by intramuscular electroporation, in healthy, HIV-uninfected adult participants
HVTN 119 is a Phase I clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using DNA plasmid (pDNA) vaccines p24CE1/2 and p55^gag, and IL-12 pDNA adjuvant.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.